Internship

MSAT Intern

Posted on 3/13/2024

Arcellx

Arcellx

51-200 employees

Develops immunotherapies for cell therapy

Biotechnology
Healthcare

North Bethesda, MD, USA + 1 more

More locations: San Carlos, CA, USA

Category
Lab & Research
Interdisciplinary Research
Life Sciences
Required Skills
PowerPoint/Keynote/Slides
Requirements
  • Enrolled in undergraduate or graduate program at the time of the internship
  • Basic understanding of Chemistry/Biology or at least taken courses in science field
  • Experience with Microsoft Office applications like Word, Excel, Powerpoint is preferred
  • Basic Laboratory skills and necessary interpersonal skills to collaborate
  • Attention to details and following instructions written in a Batch Record/Standard Operating Procedure
Responsibilities
  • Laying the foundation for transitioning from paper based to Digital Master Batch Records for CAR-T Manufacturing platform
  • Understanding and familiarization with existing paper based Master Batch Records for CAR-T Process
  • Electronic Batch Record Training
  • Learning Platform and Integration of current MBR into electronic MBR
  • Proof-of concept studies and execution of the e-BR in PD/MSAT Lab

Arcellx develops immunotherapies aimed at improving cell therapy for serious diseases. Their products work by harnessing the body's immune system to target and treat conditions that currently have limited treatment options. Unlike many competitors, Arcellx focuses specifically on proprietary immunotherapy products and has a business model that includes partnerships and licensing agreements to support their research and development efforts. The company's goal is to meet unmet medical needs by providing safe and effective treatment alternatives for patients.

Company Stage

IPO

Total Funding

$194.5M

Headquarters

Gaithersburg, Maryland

Founded

2014

Growth & Insights
Headcount

6 month growth

14%

1 year growth

23%

2 year growth

64%
Simplify Jobs

Simplify's Take

What believers are saying

  • Partnership with Kite expands development and commercialization opportunities for CART-ddBCMA.
  • Positive Phase 1 results for anito-cel show robust long-term responses in multiple myeloma.
  • Increased interest in bispecific antibodies drives innovation in cancer treatment.

What critics are saying

  • Competition from established CAR-T therapies like Abecma and Carvykti could limit market share.
  • Dependency on Gilead's Kite for development may pose strategic risks.
  • Potential delays in the Phase 3 trial for anito-cel could impact market entry.

What makes Arcellx unique

  • Arcellx's CART-ddBCMA has Fast Track and Orphan Drug designations from the FDA.
  • The ARC-SparX platform offers dosable and controllable CAR-T therapy options.
  • Anito-cel uses a novel D-Domain BCMA binder for enhanced antigen binding.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE